Drug intelligence / Profile preview

XBH116

Development stage: Preclinical
Lead developer: Shanghai XBH Biotechnology
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

XBH116 is a bispecific antibody currently in the discovery phase of development by GV20 Oncotherapy. It is being investigated for the treatment of autoimmune diseases. The therapeutic approach utilizes dual-target engagement to modulate immune pathways relevant to autoimmunity, although the specific biological targets have not yet been disclosed by the company.

Beyond the preview

Go deeper on XBH116.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XBH116.

Explore the full profile